US benchmark stock indices are set for gains when markets open today, fuelled by positive developments surrounding a Covid-19 vaccine. Russia announced today that it has registered the world’s first Covid-19 vaccine, while drug makers such as BioNTech, Novavax, and Inovio Pharmaceuticals say they are moving closer to their respective vaccines, with these stocks making some of the biggest pre-market moves.

Such developments are pushing the SP500 minis to about 0.5 percent, or a mere 18 points, away from its record high.

The headlines have also contributed to Gold prices hurtling back below the psychologically-important $2000 level. Bullion has fallen by some 2.3 percent so far today, which would mark its biggest single-day move since April. The news may have spurred on the technical pullback needed to bring Gold prices away from overbought territory. With a flood of US Treasuries being brought to market this week, there could also be some profit-taking in Bullion prices at play.

Risk appetite has also seen other tailwinds, including news that US President Donald Trump is considering a tax cut for capital gains. Investors outlook surrounding Germany, Europe’s largest economy, over the next 6 months also registered a positive surprise. Such headlines make for a risk-on mood, emboldening investors who continue to remain optimistic over the global economic recovery.

MyFxtops 邁投 (www.myfxtops.com) -Reliable Forex Copy Trade community, follow the master for free to trade!

Disclaimer: This article is reproduced from the Internet. If there is any infringement, please contact us to delete it immediately. In addition: This article only represents the personal opinion of the author and has nothing to do with Mato Finance The originality and the text and content stated in this article have not been confirmed by this site. The authenticity, completeness and timeliness of this article and all or part of the content and text are not guaranteed or promised. Please refer to it for reference only Verify the content yourself.

Copyright belongs to the author.
For commercial reprints, please contact the author for authorization. For non-commercial reprints, please indicate the source.